Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
21 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Eli Lilly Benelux from Brussel, company number BE0406754454, closed financial year 2025 with a result of € 11.5 million after tax. For that financial year Eli Lilly Benelux recorded revenue of € 294.3 million and equity of € 20.4 million. Compared with financial year 2024, the result moved from € 6.1 million to € 11.5 million. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
€ 20.4 million
▲ 2% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 11.5 million
▲ 88% vs 2024
Profit after tax over the fiscal year.
€ 11 million paid out
96 % of the profit went to the shareholders, mostly to ELI LILLY NETHERLAND BV (100 % of the shares). That is where the money ends up.
People and assets in 2025
96.6
▲ 9.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 29.7 million
▲ 20% vs 2024
€ 307,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 274,881
▲ 142% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 35.8 million
▲ 126% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 54 days on average.
€ 8.8 million
▲ 29% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 121,468,884 | € 111,072,780 | € 142,728,652 | € 294,290,277 | ▲ 106% |
| Profit after taxes | € 6,539,842 | € 4,502,742 | € 6,091,185 | € 11,465,048 | ▲ 88% |
| Equity | € 19,892,430 | € 19,895,173 | € 19,947,032 | € 20,412,079 | ▲ 2% |
| Total debts | € 20,947,440 | € 18,979,204 | € 31,495,437 | € 59,276,441 | ▲ 88% |
| Retained profit | € 7,001,430 | € 7,004,173 | € 7,056,032 | € 7,521,079 | ▲ 7% |
| Dividend | € 6,500,000 | € 4,500,000 | € 6,000,000 | € 11,000,000 | ▲ 83% |
| Balance sheet total | € 42,180,866 | € 38,874,377 | € 51,442,469 | € 79,688,520 | ▲ 55% |
| Employees (FTE) | 83 | 77.2 | 86.9 | 96.6 | ▲ 9.7 |
Key figures of Eli Lilly Benelux, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Eli Lilly Benelux?
What happened at Eli Lilly Benelux in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 11.5 million (▲ 88% vs 2024). Source: NBB ↗
- Sandrine FERRIERE stepped down as director. NBB
- Frederic CLAIS stepped down as director. NBB
- Sandrine FERRIERE became a director. NBB
- Frederic CLAIS became a director. NBB
- New establishment in Brussel. KBO
- Start of the company according to the CBE. KBO
In short
From € 6.5 million profit in 2021 to € 11.5 million profit in 2025.
Paid € 10.6 million in corporate taxes since 2021.
Best year ever: 2025, with € 11.5 million profit.
Paid out € 28 million in dividends to the owners in total.
A new publication or filing at Eli Lilly Benelux? We notify you, reason included.
Follow Eli Lilly BeneluxDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by ELI LILLY NETHERLAND BV (100%) and ELI LILLY EUROPEAN CLINICAL TRIALS SERVICES SA (0%).
Directors
According to the 2025 annual accounts
Sandrine FERRIERE
Director
since 2020 · until 2026
Frederic CLAIS
Director
since 2020 · until 2026
Shareholders
ELI LILLY NETHERLAND BV
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Markiesstraat 1
1000 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 21 companies are registered at this address.
All companies at this address →Euronext Brussels
€ 32.5 million revenue · 2025
Fonds tot bevordering van het industrieel onderzoek in Vlaanderen
Föderale Nuklearkontrollbehörde
€ 34.4 million revenue · 2025
FESTIVAL VAN VLAANDEREN INTERNATIONAAL BRUSSEL - EUROPA
€ 738,871 gross margin · 2025
Plan International Belgium
+16 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0406.754.454
- VAT number
- BE 0406.754.454
- Registered office
- Markiesstraat 1, 1000 Brussel
- Names & denominations
- Eli Lilly Benelux
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 19 June 1969
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen